HeartMate III is a next-generation continuous flow left ventricular assist device (:LVAD) based on fully magnetically levitated technology. This technology helps in reducing adverse event rates ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

November 17, 2009 (Orlando, Florida) — Advanced heart-failure transplant-ineligible patients with Thoratec's HeartMate II continuous-flow left-ventricular assist device (LVAD) have better-than-even ...

Highlights include the best six month survival documented in a LVAD CE Mark clinical study and low rates of adverse events with zero pump thrombosis events Survival with HeartMate 3 at six months was ...

PLEASANTON, Calif., Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant ...

In March Abbott Laboratories (NYSE:ABT) pulled the control unit for its HeartMate II pump off the US market. The FDA has now designated the recall class I – the most serious type – making public the ...

Patients with the HeartMate 3 had fewer of these adverse events - 28 percent of patients versus 38 percent for those on HeartMate II. Those on HeartMate 3 tended to have bleeding events, which are ...

March 12 (UPI) --The HeartMate 3, an update to one of the most widely-used left ventricle assist devices, or LVADs, in the world, showed strong long-term results during a large clinical trial, its ...

Cleveland, OH - Patients implanted with a HeartMate II (Thoratec) left ventricular assist device (LVAD) following its 2008 FDA approval have had similar outcomes to what was predicted by the ...

ORLANDO, Florida (Reuters) - Advanced heart failure patients who received Thoratec Corp's new pump awaiting U.S. approval as an alternative to heart transplants lived longer and fared far better than ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...